Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Comment by SPCEO1on Jan 26, 2023 2:20pm
147 Views
Post# 35248349

RE:We are getting optimistic

RE:We are getting optimistic As Sabbocat pointed out, insiders are blocked from trading since the end of November until after earnings are released in February. So, they can't buy even if they wanted to. Plus they will no doubt have already been granted some really low cost options. With the stock price so low and a some positive developments possible, perhaps a little optimism is called for. If we just get no negative developments, the stock should rise to a more fair value level. But since we cannot be sure of the news awaiting us on the near term horizon on earnings, write-offs, cost cutting, NASH partnership and revised TH-1902 trial protocol and timing, it is hard to get too excited about the stock in light of its past failures. Those past failures may have little to do with the future of the stock, but since we are all human, they still influence decisions. There is a chance that THTX is one of the best performing stocks of the year in 2023 as it would not take a lot to launch it much higher, but managemetn will need to take some actions that will change the negative narrative for that to happen. Or get lucky!
realitycheck4u wrote: But that's only from the fact we are sitting below $1. If this was such a great time to buy, then where are the insiders on the Board? I see no buys from them on SETI. 

 


<< Previous
Bullboard Posts
Next >>